Julie Dixon, Ph.D. is the Head of Global Regulatory Affairs for the Oncology Business Unit. She joined Takeda in January 2021 and is responsible for partnering with teams to develop and execute innovative regulatory strategies to enable the development and commercialization of life-changing therapies for patients.
Julie brings more than 20 years of pharmaceutical experience, encompassing drug discovery experience through integrating regulatory strategy into drug development and precision medicine. Prior to joining Takeda, Julie spent several years at Bristol Myers Squibb, where she held multiple roles of increasing responsibility including Global Regulatory Head of Cardiovascular and Global Regulatory Head of Early Assets Oncology and Precision Medicine.
Julie has extensive experience in leading global regulatory teams throughout all stages of development and advancing innovative regulatory approaches with Health Authorities. In addition, she led a team responsible for developing and executing global precision medicine regulatory strategies across therapeutic areas.
Before joining BMS, Julie held research and regulatory strategy positions at Bayer HealthCare Pharmaceuticals. She was a global regulatory lead in the areas of cardiovascular and diagnostic imaging and was a medicinal chemist and project leader responsible for oncology research programs.
Julie holds a Ph.D. in Synthetic Organic Chemistry from the University of Illinois, Urbana-Champaign, and conducted post-doctoral research studies at Yale University. She also holds a BS in Chemistry from the University of Michigan.